RxDoctor Payments Data

Javid Tavari, DO

Internal Medicine · Los Angeles, CANPI 1669400602

Payments from drug & device makers

$3,017in general payments, 2019–2025

Across 93 payments — averaging $32.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$701
  • Amgen$426
  • Lilly USA, LLC$281
  • Galderma Laboratories, L.p.$267
  • Boehringer Ingelheim$213
  • Eisai Inc.$140
  • plus $989 from 13 others

What the payments were for

  • Food & beverage$3,017100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,017 in reported general payments places this provider in the 85th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$754,210
Medicare patients
280
Services billed
23,317

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide62$57,472
MounjaroTirzepatide45$48,277
JardianceEmpagliflozin44$36,443
LinzessLinaclotide32$20,777
Diclofenac Sodium77$15,687
JanumetSitagliptin Phos/Metformin Hcl21$14,326
MyrbetriqMirabegron18$13,796
Trelegy ElliptaFluticasone/Umeclidin/Vilanter15$10,885
XiidraLifitegrast13$8,153
EliquisApixaban17$7,622
VascepaIcosapent Ethyl26$6,863
GemtesaVibegron13$5,736
SymbicortBudesonide/Formoterol Fumarate24$5,626
Dexlansoprazole DrDexlansoprazole19$3,325
Icosapent Ethyl19$2,881

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$70$57,47262 claims
Lilly USA, LLCMounjaro$281$48,27745 claims
Boehringer IngelheimJardiance$213$36,44344 claims
AbbVieLinzess, Synthroid$701$21,87148 claims
GSKTrelegy Ellipta$26$10,88515 claims
AstraZenecaSymbicort$51$5,62624 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Los Angeles

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →